Clinical DataDYNE-251 delivered robust muscle content-adjusted dystrophin expression and sustained effect on functional outcomes, which can enable BLA submission for accelerated approval.
Financial StabilityManagement's recent financing extended DYN's runway into 3Q27, enabling derisking of the DM1 program and commercialization of the DMD program.
Regulatory SupportThe FDA granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy, highlighting unmet need and FDA support.